Posts tagged Braeburn Pharmaceuticals
Titan Pharma in talks with Braeburn about future of Probuphine partnership

Titan Pharmaceuticals (NASDAQ:TTNP) is in discussions with Braeburn Pharmaceuticals about their partnership for the development and commercialization of Probuphine, the first six-month maintenance treatment of opioid dependence. 

Read More
Knight NDS for Probuphine in Canada accepted for review

Knight Therapeutics’ (TSX:GUD) New Drug Submission (NDS) for Probuphine, a subdermal implant of buprenorphine for the treatment of opioid drug dependence, has been accepted for review by Health Canada.

Read More
Braeburn names Mike Derkacz as president, CEO

Closely held Braeburn Pharmaceuticals appointed Michael Derkacz as president and CEO, succeeding Behshad Sheldon, who is stepping down from both posts and as a director, effective immediately, but will continue to serve as a consultant to Braeburn.

Read More
HHS to expand treatment access for war on opioid addiction

Titan Pharmaceuticals (NASDAQ:TTNP) and its marketing partner, closely-held Braeburn Pharmaceuticals, received a potential shot in the arm as the White House called for expanded access to treatment in the war on opioid addition.

Read More
Braeburn gets CMS J-code for Titan's Probuphine

Closely held Braeburn Pharmaceuticals announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) code, or permanent J-code, for Probuphine, the first and only six-month buprenorphine implant for the maintenance treatment of opioid addiction.

Read More
Braeburn files for $150-million IPO

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA.

Read More
Titan’s Probuphine, Behshad Sheldon win Stevie awards

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was named a gold award winner at the 13th annual Stevie Awards for Women in Business in the category of "Best New Product or Service of the Year."

Read More
Titan Pharma’s Kate Beebe interviewed on Facebook Live

Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP), was interviewed on Facebook Live yesterday in conjunction with the company ringing the closing bell at the exchange.

Dr. Beebe discussed Titan’s Probuphine implant, which was approved by the FDA earlier this year for the treatment of opioid addiction, and its sales and marketing partner, Braeburn Pharmaceuticals.

Read More
Titan’s Probuphine featured at ISAM meeting

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant and marketing partner, closely-held Braeburn Pharmaceuticals, were featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week.

Probuphine, a subdermal implant of buprenorphine, is the first commercially available six-month maintenance treatment for opioid dependence. The FDA approved Probuphine in May.

Read More
Popular Science picks Titan’s Probuphine for “Best of What’s New” award

Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the "12 Most Important Innovations of the Year" in the health category in Popular Science's annual Best of What's New issue.

Probuphine, a subdermal implant developed using Titan's proprietary ProNeura technology, was approved by the FDA in May, becoming the first commercially available long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.

Read More
Titan’s Probuphine gains more media attention

Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids.

Independent TV station, WHDT, in Stuart, FL. has produced a segment on Probuphine with Dr. Stuart Segal and one of his patients, who was successfully weaned off her use of opioids.

Read More
JAMA article points to effectiveness of Titan’s buprenorphine implant

A randomized clinical trial reported in the current issue of the Journal of the American Medical Association found that Titan Pharmaceuticals’ (NASDAQ:TTNP) six-month buprenorphine implant, known as Probuphine, may be an effective relapse prevention treatment for stable opioid-dependent adults maintaining clinical stability with 8 mg/d or less of sublingual buprenorphine.

Read More
Congress passes Comprehensive Addiction and Recovery Act

The United States Senate on Wednesday voted overwhelmingly to pass the Comprehensive Addiction and Recovery Act (CARA). The Senate vote follows a similar near-unanimous vote in the House of Representatives last week and will send the bill to the President for his signature.

The American Society of Addiction Medicine (ASAM) welcomed passage of the legislation and called on Congress to fulfill its commitment to fund CARA fully this year.

Read More
Braeburn provides update on training sessions for Probuphine

Healthcare provider training and certification for Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant will take place on July 15-17 in Denver by Titan’s marketing partner, closely-held Braeburn Pharmaceuticals.

The FDA cleared Probuphine in late May as the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses of buprenorphine, specifically 8 mg or less a day. Opioid use disorder is a chronic brain disease and one of the fastest growing public health epidemics in America.

Read More
Buprenorphine patient limit raised to 275

The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine.

The move was part of several announced by the administration as part of an effort to stem the opioid abuse epidemic that is killing nearly 80 people from overdoses every day.

Read More
First patients treated with Titan Pharma’s Probuphine

The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26.

ProbuphineProbuphine was developed using Titan’s long-term, continuous drug delivery platform, ProNeura, for the maintenance treatment of opioid dependence.

Read More
Braeburn presents Probuphine data at CPDD meeting

Closely-held Braeburn Pharmaceuticals has presented data from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid dependence, at the annual scientific meeting of The College on Problems of Drug Dependence (CPDD).

The FDA recently approved Probuphine, which was developed by its partner, Titan Pharmaceuticals (NASDAQ:TTNP), on May 26.

Read More
Titan Pharma receives milestone on Probuphine approval

Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the first six-month maintenance treatment of opioid dependence.

Under terms of the licensing agreement, closely-held Braeburn will pay Titan tiered royalties on net sales in the U.S. and Canada at rates ranging from the mid-teens to low-twenties. In addition, Titan is eligible for up to $165-million in milestone payments based on achievement of certain annual sales targets.

Read More
Roth ups Titan Pharma price target to $10

Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid addiction. The stock closed at $7.07 on Friday.

“The hook here is forced compliance,” writes analyst Scott Henry. “The implant removes the risk of noncompliant patients relapsing back to opioids, including heroin. Adding difficulty to the compliance of oral buprenorphine, Suboxone, is the high street value of the drug, which effectively can be sold to support an opioid habit,” he added.

Read More
Titan Pharma’s Probuphine featured on CNBC

CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the U.S.

The feature discusses the potential benefits of an implant, compared with current sublingual versions of buprenorphine, and the relatively low percentage of doctors authorized to write prescriptions for buprenorphine.

Read More